valproic acid has been researched along with Kahler Disease in 21 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effects of valproic acid (VPA) on autophagic flux in multiple myeloma (MM) cells." | 7.96 | Valproic Acid Increased Autophagic Flux in human Multiple Myeloma Cells in Vitro. ( Hao, CL; Lin, L; Wang, LH; Wang, Y; Yan, LN; Yang, Y; Zhang, RJ; Zhang, ZH, 2020) |
| "To investigate the effects of valproic acid (VPA) on autophagy in multiple myeloma (MM) cell lines RPMI8226 and U266." | 7.83 | [Valproic acid activates autophagy in multiple myeloma cell lines RPMI8226 and U266]. ( Gu, CH; Hao, CL; Li, H; Wang, TR; Yan, LN; Zhang, YY; Zhang, ZH; Zhao, L; Zhao, RJ, 2016) |
| " Histone deacetylase inhibitors such as valproic acid (VPA) are promising drugs for cancer therapy since they have been reported to have antiproliferative effects and to induce differentiation in carcinoma and leukemic cells." | 7.74 | Valproic acid induces non-apoptotic cell death mechanisms in multiple myeloma cell lines. ( Aouali, N; Berchem, G; Bosseler, M; Brons, NH; Leners, B; Palissot, V; Schwartz, C; Wack, S, 2007) |
| "The aim of this study was to evaluate the effects of valproic acid (VPA), as a histone deacetylase inhibitor, on myeloma cell lines and on sorted human bone marrow multiple myeloma cells." | 7.73 | The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. ( Fleissner, C; Heider, U; Jakob, C; Kaiser, M; Kloetzel, PM; Sezer, O; Sterz, J; Zavrski, I, 2006) |
| "BACKGROUND Multiple myeloma is featured by the proliferation of malignant plasma cell in bone marrow." | 5.56 | GANT61 and Valproic Acid Synergistically Inhibited Multiple Myeloma Cell Proliferation via Hedgehog Signaling Pathway. ( Hao, C; Li, J; Pei, X; Wang, L; Zhang, R; Zhang, Z, 2020) |
| "To investigate the effects of valproic acid (VPA) on autophagic flux in multiple myeloma (MM) cells." | 3.96 | Valproic Acid Increased Autophagic Flux in human Multiple Myeloma Cells in Vitro. ( Hao, CL; Lin, L; Wang, LH; Wang, Y; Yan, LN; Yang, Y; Zhang, RJ; Zhang, ZH, 2020) |
| "To investigate the effects of valproic acid (VPA) on autophagy in multiple myeloma (MM) cell lines RPMI8226 and U266." | 3.83 | [Valproic acid activates autophagy in multiple myeloma cell lines RPMI8226 and U266]. ( Gu, CH; Hao, CL; Li, H; Wang, TR; Yan, LN; Zhang, YY; Zhang, ZH; Zhao, L; Zhao, RJ, 2016) |
| "To investigate the effects of valproic acid(VPA) on the expression of intracellular domain of Notch1 (ICN1) and Hes1 in multiple myeloma RPMI 8226 cell line." | 3.83 | [Effects of VPA on the Expression of Notch Signaling Pathway in Multiple Myeloma RPMI 8226 Cell Line]. ( Hao, CL; Qiao, L; Wang, LH; Yan, LN; Yang, Y; Zhang, ZH; Zhao, L; Zhao, RJ, 2016) |
| "This study was aimed to investigate the apoptosis-inducing effect of valproic acid (VPA) combined with arsenic trioxide (ATO) on human multiple myeloma RPMI 8226 cells and its mechanism." | 3.80 | [Apoptosis-inducing effect of valproic acid combined with arsenic trioxide on RPMI 8226 cells and its mechanism]. ( Wang, XN; Zhang, M, 2014) |
| " Histone deacetylase inhibitors such as valproic acid (VPA) are promising drugs for cancer therapy since they have been reported to have antiproliferative effects and to induce differentiation in carcinoma and leukemic cells." | 3.74 | Valproic acid induces non-apoptotic cell death mechanisms in multiple myeloma cell lines. ( Aouali, N; Berchem, G; Bosseler, M; Brons, NH; Leners, B; Palissot, V; Schwartz, C; Wack, S, 2007) |
| "The expression of vascular endothelial growth factor receptor 1(VEGFR-1) in human multiple myeloma KM3 cells in vitro, effects of valproic acid (VPA), as a histone deacetylase inhibitor, on cell proliferation and apoptosis and the underlying molecular mechanism were investigated." | 3.74 | Histone deacetylase inhibitor valproic acid inhibits proliferation and induces apoptosis in KM3 cells via downregulating VEGF receptor. ( Dong, XF; Li, LZ; Song, Q; Wang, LQ; Zhao, CL, 2007) |
| "The aim of this study was to evaluate the effects of valproic acid (VPA), as a histone deacetylase inhibitor, on myeloma cell lines and on sorted human bone marrow multiple myeloma cells." | 3.73 | The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. ( Fleissner, C; Heider, U; Jakob, C; Kaiser, M; Kloetzel, PM; Sezer, O; Sterz, J; Zavrski, I, 2006) |
| "BACKGROUND Multiple myeloma is featured by the proliferation of malignant plasma cell in bone marrow." | 1.56 | GANT61 and Valproic Acid Synergistically Inhibited Multiple Myeloma Cell Proliferation via Hedgehog Signaling Pathway. ( Hao, C; Li, J; Pei, X; Wang, L; Zhang, R; Zhang, Z, 2020) |
| "Human multiple myeloma(MM) cells were treated with VPA of non-toxic dose in absence and presence of DOX or MEL at different concentrations (ie." | 1.42 | [Valproic Acid Represses Autophagy and Enhances the Anti-myeloma Activity of DNA-damaging Drugs]. ( Chen, XQ; Dong, BX; Gao, GX; Gu, HT; Jin, YL; Shu, MM; Tang, HL; Xu, L, 2015) |
| "Valproic acid (VPA) is a well-tolerated anticonvulsant that exerts anti-tumour activity as a histone deacetylase inhibitor." | 1.35 | In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. ( Amodio, N; Anderson, KC; Arbitrio, M; Bulotta, A; Calimeri, T; Caraglia, M; Di Martino, MT; Eramo, PO; Munshi, NC; Neri, P; Rossi, M; Tagliaferri, P; Tassone, P; Ventura, M; Viscomi, C, 2008) |
| "Multiple myeloma is still an incurable disease, most commonly occurring in the elderly." | 1.35 | Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma. ( Abe, M; Amou, H; Harada, T; Hashimoto, T; Hiasa, M; Kitazoe, KI; Matsumoto, T; Nakano, A; Oda, A; Ozaki, S; Takeuchi, K, 2009) |
| "Acute hyperammonemia is a medical emergency for which immediate steps must be taken to minimize permanent brain damage." | 1.32 | Unusual causes of hyperammonemia in the ED. ( Chen, WJ; Shih, FF; Weng, TI, 2004) |
| "Zonisamide was changed to sodium valproate." | 1.31 | Smoldering myeloma associated with zonisamide treatment. ( Ando, Y; Asai, S; Hotta, T; Kobayashi, H; Miyachi, H, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (52.38) | 29.6817 |
| 2010's | 8 (38.10) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, Z | 1 |
| Zhang, R | 1 |
| Hao, C | 1 |
| Pei, X | 1 |
| Li, J | 1 |
| Wang, L | 1 |
| Wang, Y | 2 |
| Hao, CL | 3 |
| Zhang, ZH | 3 |
| Wang, LH | 2 |
| Yan, LN | 3 |
| Zhang, RJ | 1 |
| Lin, L | 1 |
| Yang, Y | 2 |
| Liu, Z | 1 |
| Jing, Q | 1 |
| Li, Y | 1 |
| Mi, F | 1 |
| Xiang, C | 1 |
| Fu, R | 1 |
| Wang, XN | 1 |
| Zhang, M | 2 |
| Wang, X | 1 |
| Jin, YL | 1 |
| Dong, BX | 1 |
| Xu, L | 1 |
| Tang, HL | 1 |
| Gao, GX | 1 |
| Gu, HT | 1 |
| Shu, MM | 1 |
| Chen, XQ | 1 |
| Zhang, YY | 1 |
| Zhao, RJ | 2 |
| Li, H | 1 |
| Wang, TR | 1 |
| Gu, CH | 1 |
| Zhao, L | 2 |
| Qiao, L | 1 |
| Neri, P | 1 |
| Tagliaferri, P | 1 |
| Di Martino, MT | 1 |
| Calimeri, T | 1 |
| Amodio, N | 1 |
| Bulotta, A | 1 |
| Ventura, M | 1 |
| Eramo, PO | 1 |
| Viscomi, C | 1 |
| Arbitrio, M | 1 |
| Rossi, M | 1 |
| Caraglia, M | 1 |
| Munshi, NC | 1 |
| Anderson, KC | 1 |
| Tassone, P | 1 |
| Kitazoe, KI | 1 |
| Abe, M | 1 |
| Hiasa, M | 1 |
| Oda, A | 1 |
| Amou, H | 1 |
| Harada, T | 1 |
| Nakano, A | 1 |
| Takeuchi, K | 1 |
| Hashimoto, T | 1 |
| Ozaki, S | 1 |
| Matsumoto, T | 1 |
| Aouali, N | 2 |
| Palissot, V | 2 |
| El-Khoury, V | 1 |
| Moussay, E | 1 |
| Janji, B | 1 |
| Pierson, S | 1 |
| Brons, NH | 2 |
| Kellner, L | 1 |
| Bosseler, M | 2 |
| Van Moer, K | 1 |
| Berchem, G | 2 |
| Zhu, YF | 1 |
| Ye, BG | 1 |
| Shen, JZ | 1 |
| Lin, CM | 1 |
| Lin, FA | 1 |
| Shen, SF | 1 |
| Xu, CB | 1 |
| Wu, X | 1 |
| Tao, Y | 1 |
| Hou, J | 1 |
| Meng, X | 1 |
| Shi, J | 1 |
| Weng, TI | 1 |
| Shih, FF | 1 |
| Chen, WJ | 1 |
| Grubben, B | 1 |
| De Jonghe, P | 1 |
| Cras, P | 1 |
| Demey, HE | 1 |
| Parizel, PM | 1 |
| Namazi, MR | 1 |
| Kaiser, M | 1 |
| Zavrski, I | 1 |
| Sterz, J | 1 |
| Jakob, C | 1 |
| Fleissner, C | 1 |
| Kloetzel, PM | 1 |
| Sezer, O | 1 |
| Heider, U | 1 |
| Schwartz, C | 1 |
| Wack, S | 1 |
| Leners, B | 1 |
| Gómez-Benito, M | 1 |
| Martinez-Lorenzo, MJ | 1 |
| Anel, A | 1 |
| Marzo, I | 1 |
| Naval, J | 1 |
| Dong, XF | 1 |
| Song, Q | 1 |
| Li, LZ | 1 |
| Zhao, CL | 1 |
| Wang, LQ | 1 |
| Asai, S | 1 |
| Miyachi, H | 1 |
| Kobayashi, H | 1 |
| Hotta, T | 1 |
| Ando, Y | 1 |
21 other studies available for valproic acid and Kahler Disease
| Article | Year |
|---|---|
GANT61 and Valproic Acid Synergistically Inhibited Multiple Myeloma Cell Proliferation via Hedgehog Signaling Pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Drug Screening | 2020 |
Valproic Acid Increased Autophagic Flux in human Multiple Myeloma Cells in Vitro.
Topics: Antineoplastic Agents; Autophagosomes; Autophagy; Cell Line, Tumor; Cell Proliferation; Gene Express | 2020 |
The short-term effect of histone deacetylase inhibitors, chidamide and valproic acid, on the NF‑κB pathway in multiple myeloma cells.
Topics: Acetylation; Aminopyridines; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Histone De | 2019 |
[Apoptosis-inducing effect of valproic acid combined with arsenic trioxide on RPMI 8226 cells and its mechanism].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Caspase 8; Caspase 9; Cell Line | 2014 |
Synergistic effects of valproic acid and arsenic trioxide on RPMI8226 cells in vitro and the possible underlying mechanisms.
Topics: Acetylation; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Caspase 8; Caspase | 2015 |
[Valproic Acid Represses Autophagy and Enhances the Anti-myeloma Activity of DNA-damaging Drugs].
Topics: Acetylation; Autophagy; Cell Line, Tumor; Cell Proliferation; DNA; DNA Damage; Doxorubicin; Humans; | 2015 |
[Valproic acid activates autophagy in multiple myeloma cell lines RPMI8226 and U266].
Topics: Apoptosis; Autophagy; Beclin-1; Cell Line, Tumor; Cell Proliferation; Humans; Microtubule-Associated | 2016 |
[Effects of VPA on the Expression of Notch Signaling Pathway in Multiple Myeloma RPMI 8226 Cell Line].
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Humans; Multiple Myeloma; RNA, Mes | 2016 |
In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Proliferation; Dose-Response Relationshi | 2008 |
Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Proliferation; Cell Survival; Cocu | 2009 |
Peroxisome proliferator-activated receptor gamma agonists potentiate the cytotoxic effect of valproic acid in multiple myeloma cells.
Topics: Acetylation; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspa | 2009 |
[Inhibitory effect of VPA on multiple myeloma U266 cell proliferation and regulation of histone acetylation].
Topics: Acetylation; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Histone Deacetylase 1; Histone Deacet | 2010 |
Valproic acid upregulates NKG2D ligand expression through an ERK-dependent mechanism and potentially enhances NK cell-mediated lysis of myeloma.
Topics: Cell Line, Tumor; Extracellular Signal-Regulated MAP Kinases; GPI-Linked Proteins; Histocompatibilit | 2012 |
Unusual causes of hyperammonemia in the ED.
Topics: Adult; Aged; Anticonvulsants; Antimetabolites, Antineoplastic; Emergency Service, Hospital; Female; | 2004 |
Valproate-induced hyperammonemic encephalopathy: imaging findings on diffusion-weighted MRI.
Topics: Brain; Brain Mapping; Diffusion Magnetic Resonance Imaging; Epilepsy; Humans; Male; Middle Aged; Mul | 2004 |
The potential utility of sodium valproate as a novel addition to anti-multiple myeloma armamentarium.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Gene Expression Regulation, Neoplast | 2005 |
The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma.
Topics: Apoptosis; Cell Cycle; Cell Proliferation; Histone Deacetylase Inhibitors; Humans; Multiple Myeloma; | 2006 |
Valproic acid induces non-apoptotic cell death mechanisms in multiple myeloma cell lines.
Topics: Apoptosis; Cadaverine; Carcinoma; Caspases; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Survival; | 2007 |
Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.
Topics: Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Cell Line, Tumor; Cell Membr | 2007 |
Histone deacetylase inhibitor valproic acid inhibits proliferation and induces apoptosis in KM3 cells via downregulating VEGF receptor.
Topics: Acetylation; Apoptosis; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Enzym | 2007 |
Smoldering myeloma associated with zonisamide treatment.
Topics: Adult; Agammaglobulinemia; Anticonvulsants; Epilepsy, Generalized; Humans; Immunoglobulin lambda-Cha | 2002 |